Dr. Tareq Abadl: What If Blood Matching Went Deeper than Just ABO and Rh?
Dr. Tareq Abadl, Medical Laboratory Specialist and Director of the Blood Bank at Dr. Abdelkader Al-Mutawakkil Hospital, shared a post on LinkedIn:
“Precision Transfusion Medicine
What if blood matching went deeper than just ABO and Rh?
Molecular blood-group genotyping analyzes a patient’s blood-group genes to predict dozens of clinically significant antigens — transforming modern transfusion practice.
1. Deeper and Safer Matching
Genotyping identifies variant and weak alleles that routine serology may miss, such as:
Weak/Partial D variants
Rh, Kell, Kidd, Duffy, and MNS variants
This reduces the risk of alloimmunization, especially in patients requiring chronic transfusions (e.g., sickle cell disease, thalassemia).
2. Faster Compatible Unit Selection
Creating a genotyped donor registry allows rapid identification of best-matched units, which is crucial for patients with:
Multiple alloantibodies
Rare or complex phenotypes
3. Improved Antenatal Care
Molecular typing enhances:
Prediction of fetal antigen status
Early assessment of hemolytic disease of the fetus and newborn (HDFN)
Guidance on monitoring and intervention
4. Practical Limitations
Genotyping is powerful but works alongside serology, not as a replacement:
It predicts antigen expression, which may not always equal phenotype
Results can be affected after allogeneic stem-cell transplant or recent transfusion
Use buccal swabs or pre-transfusion samples when needed
Requires proper quality control and expert interpretation
5. Better Donor Strategy and Inventory
Molecular typing helps:
Recruit and flag rare-donor phenotypes
Improve blood-bank inventory management
Provide safer, more reliable matching for high-risk patients
How You Can Act
For Transfusion Professionals:
Implement targeted genotyping for chronically transfused or alloimmunized patients.
For Blood Donors:
Join local rare-donor programs if available — you may save lives in ways only a few can.
Find more posts featuring Dr. Tareq Abadl on Hemostasis Today.
-
Jan 30, 2026, 11:38Aaron Rodriguez Calienes on Intracranial Stenting: Rescue vs First-Line Outcomes
-
Jan 30, 2026, 11:25Ahmed Nasreldein on Sex Disparities in Thrombolysis Delay Among Egyptian Stroke Patients
-
Jan 30, 2026, 11:17Yanki Yarman: My PhD Project Has Been Published in Blood!
-
Jan 30, 2026, 11:08Alexandros Apostolou on Complications Associated with IDU and Thrombophilia
-
Jan 30, 2026, 10:57Peisong Ma on GRK5 Polymorphism Affecting Platelets
-
Jan 30, 2026, 10:47Ashok Yadav Explains Fetal Thrombotic Vasculopathy: FTV
-
Jan 30, 2026, 10:34Saif ur Rahman Compares K2 and K3 EDTA: Key Differences Explained
-
Jan 30, 2026, 10:22Manpreet Gill on Heparin Resistance: When 14 Years of Experience Finally Gets a Plot Twist
-
Jan 30, 2026, 10:14Mohamed Elsaid on The Role of Hyperlipidemia in Thrombogenesis